ArticleJournal of Cancer2026
RNF216 as a Promising Biomarker for Prognosis, Immunotherapy, and Chemotherapy in LIHC: A Comprehensive Pan-Cancer Analysis and Experimental Validation.
Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: RNF216 belongs to the E3 ubiquitin ligase family and plays a role in the development of various diseases. However, its systematic role in pan-cancer development has not been systematically explored. Methods: Publicly available data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA) were utilized. The analysis was conducted using R software and online platforms such as STRING, TISIDB, and TISCH to evaluate the role of RNF216. CCK-8 and other experiments have confirmed the function of RNF216 in liver hepatocellular carcinoma (LIHC). Results: RNF216 was significantly elevated in most tumor tissues relative to adjacent normal tissues; meanwhile, the mutation rate of RNF216 in LIHC tissues was also significantly elevated relative to normal tissues. The expression levels of RNF216 vary in tumor mutational burden (TMB) and microsatellite instability (MSI) across different tumors. It demonstrated significant diagnostic and prognostic value and was associated with clinicopathologic features in multiple cancers, especially in LIHC. The protein-protein interaction (PPI) network and GSCALite suggested that RNF216 and its co-expressed genes may promote tumor growth by regulating mitosis, cell death, and DNA damage. Gene Set Enrichment Analysis (GSEA) further revealed a positive correlation between RNF216 and cell cycle regulation pathways. RNF216 is significantly related to immune cell infiltration and expressed in various types of immune cells. Knockout of RNF216 mediated by siRNA inhibits cell proliferation and reduces the migration and invasion capability of HepG2 and Hep3B cells. Conclusion: RNF216 is strongly upregulated in various tumors, including LIHC, and plays an extremely important role in tumor diagnosis and prognosis. Targeted knockout of RNF216 is beneficial for improving the efficacy of immunotherapy and chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.